These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37534337)

  • 1. Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.
    Riaz R; Khan A; Siddiqui T
    Rare Tumors; 2023; 15():20363613231193566. PubMed ID: 37534337
    [No Abstract]   [Full Text] [Related]  

  • 2. Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e103-e104. PubMed ID: 37339097
    [No Abstract]   [Full Text] [Related]  

  • 3. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glofitamab (Columvi) for diffuse large B-cell lymphoma.
    Med Lett Drugs Ther; 2023 Aug; 65(1682):e129-e130. PubMed ID: 37516899
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epcoritamab-bysp.
    Am J Health Syst Pharm; 2023 Sep; 80(19):1289-1292. PubMed ID: 37471178
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
    Mhibik M; Gaglione EM; Eik D; Herrick J; Le J; Ahn IE; Chiu C; Wielgos-Bonvallet M; Hiemstra IH; Breij ECW; Chen J; Reilly EB; Epling-Burnette PK; Szafer-Glusman E; Sun C; Wiestner A
    Blood Adv; 2023 Aug; 7(15):4089-4101. PubMed ID: 37219524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
    Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M
    Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epcoritamab is active in large B cell lymphomas.
    Romero D
    Nat Rev Clin Oncol; 2023 Mar; 20(3):138. PubMed ID: 36646813
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. My treatment approach to patients with diffuse large B-cell lymphoma.
    Armitage JO
    Mayo Clin Proc; 2012 Feb; 87(2):161-71. PubMed ID: 22305028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diffuse Large B cell Lymphoma -  Modern Dia-gnostics and Molecularly Targeted Treatment].
    Pytlík R; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S64-72. PubMed ID: 26489504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
    Wilson WH; Bromberg JE; Stetler-Stevenson M; Steinberg SM; Martin-Martin L; Muñiz C; Sancho JM; Caballero MD; Davidis MA; Brooimans RA; Sanchez-Gonzalez B; Salar A; González-Barca E; Ribera JM; Shovlin M; Filie A; Dunleavy K; Mehrling T; Spina M; Orfao A
    Haematologica; 2014 Jul; 99(7):1228-35. PubMed ID: 24727817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Lu CH; Lee KF; Chen CC; Chen YY; Huang CE; Tsai PS; Tsou HY; Chou HJ; Chen MF; Chen PT; Lee KD; Lung J
    Jpn J Clin Oncol; 2014 Dec; 44(12):1164-71. PubMed ID: 25320341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.